CYTE Global
Frank Misselwitz is a seasoned executive with extensive experience in the pharmaceutical industry, currently serving as a Member of the Board of Directors at CYTE Global since September 2021. Previously, Frank held the position of Chief Medical Officer and Board Member at ACTIMED THERAPEUTICS LTD from August 2018 to December 2024, and served as Corporate Vice President at Bayer Pharmaceuticals from April 2005 to January 2021, where notable achievements included leading the development of Xarelto© (Rivaroxaban), recognized for one of the fastest drug development timelines globally. Frank's career also includes senior roles at Bayer HealthCare, Abbott Laboratories, and Knoll AG, alongside a foundational role at the Institute for Cardiovascular Research in Berlin. Frank holds advanced education from INSEAD and the Royal College of Surgeons in London.
This person is not in any teams
This person is not in any offices
CYTE Global
CYTE is a unique CRO powered by a global network of over 3,000 sites in 45 countries. Our online platform enables seamless collaboration between sites, sponsors, and study management. We also offer a suite of support services such as data analytics and medical writing to ensure your study gets across the line. CYTE was established as the delivery arm of the Thrombosis Research Institute (TRI) in London. TRI has been conducting scientific, clinical and outcomes research in cardiovascular disease for over 30 years. CYTE now delivers these world-leading capabilities in partnership with sponsors around the world.